ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 706,89
0,00%
Dow Jones
39 411,21
0,67%
DAX
18 325,58
0,77%
Brent Oil
85,245
-0,03%
Bitcoin
60 983,31
1,20%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Recro Pharma Inc (REPH)

  7. Recro Pharma Inc (REPH) Actualités

REPH

Recro Pharma (REPH)

Recro Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:REPH
DateHeureSourceTitreSymboleSociété
06/06/202322h38Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:REPHRecro Pharma Inc
02/06/202322h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:REPHRecro Pharma Inc
26/05/202322h08Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:REPHRecro Pharma Inc
22/05/202323h11Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:REPHRecro Pharma Inc
06/04/202314h26Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:REPHRecro Pharma Inc
24/03/202321h07Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:REPHRecro Pharma Inc
01/03/202323h01Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:REPHRecro Pharma Inc
01/03/202322h52Edgar (US Regulatory)Annual Report (10-k)NASDAQ:REPHRecro Pharma Inc
16/12/202223h01Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:REPHRecro Pharma Inc
13/12/202223h29Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:REPHRecro Pharma Inc
09/11/202222h30Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:REPHRecro Pharma Inc
07/09/202201h13Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:REPHRecro Pharma Inc
05/07/202222h37Edgar (US Regulatory)Amended Tender Offer Statement by Issuer (sc To-i/a)NASDAQ:REPHRecro Pharma Inc
27/06/202223h22Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:REPHRecro Pharma Inc
01/06/202223h06Edgar (US Regulatory)Tender Offer Statement by Issuer (sc To-i)NASDAQ:REPHRecro Pharma Inc
20/04/202223h45Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:REPHRecro Pharma Inc
04/04/202212h01Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:REPHRecro Pharma Inc
21/03/202212h00GlobeNewswire Inc.Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and TransformationNASDAQ:REPHRecro Pharma Inc
01/03/202222h05GlobeNewswire Inc.Recro Reports Fourth Quarter and Year End 2021 Financial ResultsNASDAQ:REPHRecro Pharma Inc
23/02/202213h00GlobeNewswire Inc.Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego FacilityNASDAQ:REPHRecro Pharma Inc
22/02/202222h05GlobeNewswire Inc.Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022NASDAQ:REPHRecro Pharma Inc
14/02/202222h36Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:REPHRecro Pharma Inc
11/02/202212h08Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:REPHRecro Pharma Inc
26/01/202213h00GlobeNewswire Inc.Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer PreventionNASDAQ:REPHRecro Pharma Inc
19/01/202213h00GlobeNewswire Inc.Recro Appoints Eduardo Uribe as Head of Quality for Recro San DiegoNASDAQ:REPHRecro Pharma Inc
18/01/202213h20Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:REPHRecro Pharma Inc
14/01/202223h31Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:REPHRecro Pharma Inc
06/01/202222h05GlobeNewswire Inc.Recro Reports Inducement Grants For New StaffNASDAQ:REPHRecro Pharma Inc
03/01/202213h00GlobeNewswire Inc.Recro to Present at H.C. Wainwright BioConnect 2022 ConferenceNASDAQ:REPHRecro Pharma Inc
02/12/202113h00GlobeNewswire Inc.Recro to Present at Stephens Annual Investment ConferenceNASDAQ:REPHRecro Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:REPH

Dernières Valeurs Consultées

COIN
CKSGBP
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés